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A recent Science paper reported a purine derivative that expands human cord blood hematopoietic stem
cells in culture (Boitano et al., 2010) by antagonizing the aryl hydrocarbon receptor. Major problems need
to be overcome before ex vivo HSC expansion can be used clinically.The use of human umbilical cord blood
(CB) as a source of hematopoietic stem
cells (HSCs) for transplantation continues
to increase, with more than 3000 CB
transplants performed annually around
the world (Foeken et al., 2010). Recent
growth in CB transplantation has been
fuelled by the availability of these cells in
banks as well as strong clinical data sup-
porting the use of HLAmismatched trans-
plants with low risk of graft versus-host
disease (GVHD) (Hwang et al., 2007).
However, wide utilization of CB is limited
by the relatively low number of HSCs per
unit, and most CB units have insufficient
stem cells for adults. Significant effort
has gone into developing technologies
for ex vivo expansion of HSCs in order
to enable CB transplants for adults, who
comprise the majority of patients who
need such intervention.
Boitano and colleagues recently re-
ported a purine derivative termed SR1
that significantly expands human CB
HSCs in culture (Boitano et al., 2010).
The authors screened a chemical library
of 100,000 heterocyclic compounds for
their ability to expand the numbers of
CD34+ CB cells in culture. They showed
that SR1 supported a 50-fold increase in
CD34+ cells and, more importantly, a
17-fold increase in cells that retain the
ability to engraft immunodeficient mice.
Strikingly, SR1 is an antagonist of the
aryl hydrocarbon nuclear receptor protein
(AhR), which normally mediates xenobi-
otic responses but has also been impli-
cated in regulating hematopoietic stem/
progenitor cells. Knockdown of the AhR
resulted in sustained proliferation of
CD34+ cells in culture.This study is significant because it
demonstrates that small synthetic chemi-
cals can be used to identify signaling
pathways that govern HSC fate decisions
and modulate them to allow HSC expan-
sion for clinical use.
An important caveat to consider re-
garding the capacity of SR1 to expand
HSCs is that this factor is not effective if
added alone to the culture medium. The
results presented by Boitano and col-
leagues were done in a serum-free
medium supplemented with four cyto-
kines: thrombopoietin (Tpo), stem cell
factor (SCF), Flt3 ligand, and IL-6. Their
observed maximal HSC expansion was
similar to the 20-fold expansion of human
CBHSCs obtained in a serum-free culture
medium containing a different growth
factor cocktail: SCF, Tpo, FGF-1, Angio-
poietin-like 5, and insulin-like growth
factor binding protein 2 (IGFBP2) (Zhang
et al., 2008). Many other factors and
cytokines may promote ex vivo HSC ex-
pansion, including Notch ligands, Wnts,
Bone Morphogenetic Proteins, Insulin-
like growth factor 2 (IGF-2) (Zhang and
Lodish, 2008), pleiotrophin (Himburg
et al., 2010), and prostaglandin E2 (North
et al., 2007), but none of these signal
activators have been successful when
added alone.
Because few laboratories have attemp-
ted to systematically optimize the combi-
nation and concentrations of cytokines
and other factors such as SR1, or the
time of culture or the O2 tension, it is
likely that one can significantly increase
the extent of HSC expansion ex vivo.
Methods that improve HSC homing and
survival after injection of HSCs couldCell Stem Cellalso be combined with ex vivo HSC
expansion to further enhance the effi-
ciency of transplantation.
In any case, in addition to optimizing
HSC expansion protocols, many other
hurdles remain to be overcome before
these important laboratory discoveries
can be converted into human therapies.
One important example is that CB units
are stored frozen, and thawing typically
reduces the number of viable nucleated
cells by half. Improvements in cryopreser-
vation are essential.
Another important point to consider
regarding the various protocols that are
used to expand CB HSCs is the relative
merits of preisolation of a subpopulation
of CB cells prior to the culture period.
Most of these assays begin with magnetic
bead isolation of CD34+ or CD133+ cells.
These populations contain most of the
hematopoietic progenitors and long-
term reconstituting HSCs, which are
necessary for a successful clinical graft.
Preisolation of CD34+ or CD133+ cells
improves cell expansion ex vivo, possibly
due to the absence of more mature popu-
lations or other nonhematopoietic cells
that may inhibit HSC or progenitor prolif-
eration. Working with purified progenitor
cell populations would also facilitate
eventual gene therapy approaches that
require selection of HSCs that have in-
corporated a transgene into a desired
chromosomal location.
On the other hand, preisolation of
CD34+ or CD133+ cells presents several
potential disadvantages, particularly
given that many, if not most of the HSCs
present in the original unfrozen CB unit
may be lost during this fractionation7, October 8, 2010 ª2010 Elsevier Inc. 427
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failure to capture the desired cells, given
that positive selection always leads to
cell loss due to inefficient binding to the
beads, and some HSCs may not express
enough CD34 or CD133 on their surface
to be selected. There may also be inad-
vertent cell loss due to stress and even-
tual death during the various manipulation
steps.
In the clinical setting, the final number
of HSCs and progenitors in the transplant
is the essential parameter. Given the likely
loss of a substantial number of HSCs prior
to manipulation of the CB unit, even the
current, improved, degree of HSC expan-
sion that has been achieved may not
result in an appreciative net increase in
HSC number when compared to unma-
nipulated CB units. Thus, any isolation
process that results in extensive HSC
loss should clearly be avoided in order
to maximize the number of stem cells
transplanted into the patient.
In addition to the risk of losing unse-
lected cells, the use of positive selection
methods to enrich for HSCs also involves
tagging the cells of interest with anti-
bodies, which could affect cell function
or activation state. Furthermore, this
practice also raises quality-control issues
because the antibodies remain attached
to the HSCs after transfer to the patient.
The cost of sufficient clinical grade anti-
body used to select greater than 109 cells
per CB unit is also a concern, especially
because many of the red blood cells that
are present will nonspecifically bind the
antibody and make the process ineffi-
cient. One option to overcome these limi-
tations is to use a negative depletion
method to remove non-HSCs, such as
lineage positive, differentiated, hemato-
poietic cells. Negative depletion methods
should also minimize the loss of HSCs
relative to positive selection, although
the degree of enrichment for HSCs in the
selected population will be lower.428 Cell Stem Cell 7, October 8, 2010 ª2010Therefore, given the current clinical
situation, expansion of CB cells without
positive selection seems most practical
and cost-effective. It remains to be seen
whether SR1, in combination with other
cytokines, can still expand HSCs effi-
ciently from a coarsely purified population
of HSCs, or even from unpurified total CB
cells.
In addition to various combinations of
soluble factors, several protocols for
HSC expansion involve coculture with
mesenchymal stem/stromal cell (MSC)
lines (Robinson et al., 2006). This ap-
proach offers several advantages, partic-
ularly that preisolation of CD34+ or
CD133+ cells does not appear to be
required to yield a significant expansion
of primitive cells, and that cell viability is
retained during the expansion process.
Despite these positive features, there is
little evidence that MSC coculture sup-
ports expansion of long-term reconstitut-
ing HSCs, although these conditions do
increase the number of hematopoietic
progenitors. Furthermore, challenges in
production and quality control of clinical
grade MSCs under good manufacturing
protocols (GMP) will hinder the thera-
peutic use of these cocultures, as will
the inevitable risks to the patient following
inadvertent infusions of the feeder cells,
possibly including graft reactions.
Besides HSCs, successful grafts must
include less primitive hematopoietic pro-
genitors in order to generate mature
myeloid and lymphoid cells during the first
weeks following transplantation. Immune
cells such as T cells in the graft also play
a role in the engraftment process. A re-
cent clinical study (Delaney et al., 2010)
showed that Notch-mediated ex vivo
expansion of human CD34+ CB progeni-
tors resulted in a marked increase in the
absolute number of stem/progenitor cells.
When infused in myoablated patients, the
time to neutrophil recovery was substan-
tially shortened. This finding is clinicallyElsevier Inc.important, given that delayed engraftment
can result in a higher incidence of infec-
tion, which is one of the major causes of
mortality after transplantation.
Finally, bioprocess and scale-up issues
are relevant even if MSC coculture is not
required. Milliliter volume cell cultures
are very different from multiliter cultures
that will be necessary for generating
sufficient cell numbers for clinical trans-
plants. Issues concerning absolute ster-
ility and good manufacturing practices
are needed for clinical translation (A¨hr-
lund-Richter et al., 2009), but foreign to
most laboratory investigators.REFERENCES
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